ReShape Lifesciences Inc. (NASDAQ:RSLS - Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.04 and traded as high as $7.30. ReShape Lifesciences shares last traded at $6.55, with a volume of 330,581 shares.
ReShape Lifesciences Stock Performance
The stock's fifty day moving average is $11.63 and its two-hundred day moving average is $72.12. The firm has a market capitalization of $2.71 million, a price-to-earnings ratio of -0.02 and a beta of 1.48.
ReShape Lifesciences (NASDAQ:RSLS - Get Free Report) last released its quarterly earnings results on Friday, April 4th. The medical device company reported ($47.25) earnings per share for the quarter, beating analysts' consensus estimates of ($101.50) by $54.25. The business had revenue of $1.81 million during the quarter, compared to analyst estimates of $3.17 million. ReShape Lifesciences had a negative net margin of 86.36% and a negative return on equity of 179.83%. During the same period last year, the business earned ($2,771.75) EPS.
About ReShape Lifesciences
(
Get Free Report)
ReShape Lifesciences Inc provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus.
Further Reading
Before you consider ReShape Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ReShape Lifesciences wasn't on the list.
While ReShape Lifesciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
